Published in Chembiochem on July 21, 2008
Development of sulfonamide AKT PH domain inhibitors. Bioorg Med Chem (2011) 0.85
A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery. ACS Chem Biol (2012) 0.81
The "Other" Inositols and Their Phosphates: Synthesis, Biology, and Medicine (with Recent Advances in myo-Inositol Chemistry). Angew Chem Int Ed Engl (2015) 0.80
Multivalent benzene polyphosphate derivatives are non-Ca(2+)-mobilizing Ins(1,4,5)P3 receptor antagonists. Messenger (Los Angel) (2012) 0.77
Crystal Structures of Type-II Inositol Polyphosphate 5-Phosphatase INPP5B with Synthetic Inositol Polyphosphate Surrogates Reveal New Mechanistic Insights for the Inositol 5-Phosphatase Family. Biochemistry (2016) 0.75
Fibrinogen - a possible extracellular target for inositol phosphates. Messenger (Los Angel) (2012) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Inositol trisphosphate and calcium signalling. Nature (1993) 25.57
The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol (2000) 19.46
The selectivity of protein kinase inhibitors: a further update. Biochem J (2007) 15.73
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
The Cationminus signpi Interaction. Chem Rev (1997) 7.56
PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci (2001) 6.11
Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature (1992) 4.46
High-resolution structure of the pleckstrin homology domain of protein kinase b/akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr Biol (2002) 2.92
Cation-pi interactions in ligand recognition and catalysis. Trends Pharmacol Sci (2002) 2.75
The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature (1992) 2.64
Structure of the inositol 1,4,5-trisphosphate receptor binding core in complex with its ligand. Nature (2002) 2.30
Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo. PLoS Biol (2007) 2.28
Protein kinase B/Akt at a glance. J Cell Sci (2005) 2.18
Cation-pi bonding and amino-aromatic interactions in the biomolecular recognition of substituted ammonium ligands. Biochem J (1996) 1.74
The role of phosphatases in inositol signaling reactions. J Biol Chem (1999) 1.54
Soluble and particulate Ins(1,4,5)P3/Ins(1,3,4,5)P4 5-phosphatase in bovine brain. Eur J Biochem (1989) 1.16
A portrait of AKT kinases: human cancer and animal models depict a family with strong individualities. Cancer Biol Ther (2004) 1.11
InsP4 facilitates store-operated calcium influx by inhibition of InsP3 5-phosphatase. Nature (2000) 1.11
Cloning and expression of human brain type I inositol 1,4,5-trisphosphate 5-phosphatase. High levels of mRNA in cerebellar Purkinje cells. FEBS Lett (1994) 0.95
Biphenyl 2,3',4,5',6-pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca2+ responses in rat hepatocytes. FASEB J (2007) 0.93
Synthesis of selective non-Ca(2+)-mobilizing inhibitors of D-myo-inositol 1,4,5-trisphosphate 5-phosphatase. J Med Chem (1994) 0.92
Metabolism of synthetic inositol trisphosphate analogs. J Biol Chem (1988) 0.92
The SH2 domain containing inositol 5-phosphatase SHIP2 controls phosphatidylinositol 3,4,5-trisphosphate levels in CHO-IR cells stimulated by insulin. Biochem Biophys Res Commun (2001) 0.88
Novel inositol phospholipid headgroup surrogate crystallized in the pleckstrin homology domain of protein kinase Balpha. ACS Chem Biol (2007) 0.87
Modification at C2 of myo-inositol 1,4,5-trisphosphate produces inositol trisphosphates and tetrakisphosphates with potent biological activities. Eur J Biochem (1994) 0.86
Design of potent and selective inhibitors of myo-inositol 1,4,5-trisphosphate 5-phosphatase. Biochemistry (1994) 0.83
3-hydroxybenzene 1,2,4-trisphosphate, a novel second messenger mimic and unusual substrate for type-I myo-inositol 1,4,5-trisphosphate 5-phosphatase: Synthesis and physicochemistry. Chembiochem (2006) 0.82
Interaction of benzene 1,2,4-trisphosphate with inositol 1,4,5-trisphosphate receptor and metabolizing enzymes. Eur J Pharmacol (1993) 0.81
D-myo-inositol 1,4,5-trisphosphate analogues modified at the 3-position inhibit phosphatidylinositol 3-kinase. J Biol Chem (1995) 0.79
The model student: what chemical model systems can teach us about biology. Nat Chem Biol (2007) 0.79
Deoxygenated inositol 1,4,5-trisphosphate analogues and their interaction with metabolic enzymes. (1R,2R,4R)-cyclohexane-1,2,4-tris(methylenesulfonate): a potent selective 5-phosphatase inhibitor. J Med Chem (1993) 0.77
A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol (2006) 2.57
Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J (2004) 1.77
Identification of mammalian Vps24p as an effector of phosphatidylinositol 3,5-bisphosphate-dependent endosome compartmentalization. J Biol Chem (2003) 1.76
Regulation of Ins(3,4,5,6)P(4) signaling by a reversible kinase/phosphatase. Curr Biol (2002) 1.69
Determination of neo- and D-chiro-inositol hexakisphosphate in soils by solution 31P NMR spectroscopy. Environ Sci Technol (2012) 1.53
Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res (2004) 1.49
Reversible Ser/Thr SHIP phosphorylation: a new paradigm in phosphoinositide signalling?: Targeting of SHIP1/2 phosphatases may be controlled by phosphorylation on Ser and Thr residues. Bioessays (2012) 1.40
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res (2005) 1.38
Inositol 1,3,4,5-tetrakisphosphate negatively regulates phosphatidylinositol-3,4,5- trisphosphate signaling in neutrophils. Immunity (2007) 1.33
NAADP-mediated Ca2+ signaling via type 1 ryanodine receptor in T cells revealed by a synthetic NAADP antagonist. Proc Natl Acad Sci U S A (2009) 1.30
Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene (2004) 1.28
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem (2006) 1.25
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res (2006) 1.24
Inositol 1,3,4,5-tetrakisphosphate is essential for T lymphocyte development. Nat Immunol (2003) 1.16
Differential redox regulation within the PTP superfamily. Cell Signal (2007) 1.15
Inositol 1,3,4,5-tetrakisphosphate controls proapoptotic Bim gene expression and survival in B cells. Proc Natl Acad Sci U S A (2007) 1.12
The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases. Adv Enzyme Regul (2003) 1.12
Synthetic partial agonists reveal key steps in IP3 receptor activation. Nat Chem Biol (2009) 1.12
Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulfamates. Int J Cancer (2004) 1.11
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res (2006) 1.10
Novel non-steroidal inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol (2007) 1.10
17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer (2008) 1.10
Novel 18beta-glycyrrhetinic acid analogues as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenases. Bioorg Med Chem (2004) 1.10
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res (2006) 1.09
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activity. J Med Chem (2007) 1.04
Phosphoinositide phosphatases in a network of signalling reactions. Pflugers Arch (2007) 1.03
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res (2008) 1.02
A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents. J Med Chem (2005) 1.02
Developmental defects and rescue from glucose intolerance of a catalytically-inactive novel Ship2 mutant mouse. Cell Signal (2012) 1.00
Rapid functional assays of recombinant IP3 receptors. Cell Calcium (2005) 0.99
Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate. J Med Chem (2010) 0.99
Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol (2003) 0.98
Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol (2005) 0.98
2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat (2007) 0.98
Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. Brain (2010) 0.98
PTEN M-CBR3, a versatile and selective regulator of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5). Evidence for Ins(1,3,4,5,6)P5 as a proliferative signal. J Biol Chem (2003) 0.98
Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates. Int J Cancer (2005) 0.97
Cloning and expression of a full-length cDNA encoding human inositol 1,4,5-trisphosphate 3-kinase B. Biochem Biophys Res Commun (2002) 0.97
The influence of anionic lipids on SHIP2 phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase activity. Cell Signal (2006) 0.97
Catalysis-associated conformational changes revealed by human CD38 complexed with a non-hydrolyzable substrate analog. J Biol Chem (2007) 0.95
Phosphodiesterase inhibition in heart failure. Heart Fail Rev (2008) 0.95
Steroid sulfatase: a new target for the endocrine therapy of breast cancer. Oncologist (2007) 0.94
Regulation of casein kinase-2 (CK2) activity by inositol phosphates. J Biol Chem (2004) 0.94
Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem (2008) 0.94
The g5R (D250) gene of African swine fever virus encodes a Nudix hydrolase that preferentially degrades diphosphoinositol polyphosphates. J Virol (2002) 0.93
Visualization of inositol phosphate-dependent mobility of Ku: depletion of the DNA-PK cofactor InsP6 inhibits Ku mobility. Nucleic Acids Res (2004) 0.93
Rapid synthetic route toward structurally modified derivatives of cyclic adenosine 5'-diphosphate ribose. J Org Chem (2005) 0.93
scyllo-inositol pentakisphosphate as an analogue of myo-inositol 1,3,4,5,6-pentakisphosphate: chemical synthesis, physicochemistry and biological applications. Chembiochem (2006) 0.93
Adenophostin A and analogues modified at the adenine moiety: synthesis, conformational analysis and biological activity. Org Biomol Chem (2004) 0.93
Phosphatidylinositol 3,4,5-trisphosphate: an early mediator of insulin-stimulated sodium transport in A6 cells. Am J Physiol Renal Physiol (2004) 0.93
Cloning and characterisation of hAps1 and hAps2, human diadenosine polyphosphate-metabolising Nudix hydrolases. BMC Biochem (2002) 0.93
Synthesis of stable and cell-type selective analogues of cyclic ADP-ribose, a Ca(2+)-mobilizing second messenger. Structure--activity relationship of the N1-ribose moiety. J Am Chem Soc (2005) 0.93
Biphenyl 2,3',4,5',6-pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca2+ responses in rat hepatocytes. FASEB J (2007) 0.93
The enzymes of human diphosphoinositol polyphosphate metabolism. FEBS J (2013) 0.92
Chimeric microtubule disruptors. Chem Commun (Camb) (2010) 0.92
First synthetic analogues of diphosphoinositol polyphosphates: interaction with PP-InsP5 kinase. Chem Commun (Camb) (2012) 0.92
Synthesis and Ca2+-mobilizing activity of purine-modified mimics of adenophostin A: a model for the adenophostin-Ins(1,4,5)P3 receptor interaction. J Med Chem (2003) 0.92
Regioselective hydrolysis of myo-inositol 1,3,5-orthobenzoate via a 1,2-bridged 2'-phenyl-1',3'-dioxolan-2'-ylium ion provides a rapid route to the anticancer agent Ins(1,3,4,5,6)P5. Chem Commun (Camb) (2006) 0.92
Interactions of inositol 1,4,5-trisphosphate (IP(3)) receptors with synthetic poly(ethylene glycol)-linked dimers of IP(3) suggest close spacing of the IP(3)-binding sites. J Biol Chem (2002) 0.92
The three isoenzymes of human inositol-1,4,5-trisphosphate 3-kinase show specific intracellular localization but comparable Ca2+ responses on transfection in COS-7 cells. Biochem J (2003) 0.92
Binding of inositol 1,4,5-trisphosphate (IP3) and adenophostin A to the N-terminal region of the IP3 receptor: thermodynamic analysis using fluorescence polarization with a novel IP3 receptor ligand. Mol Pharmacol (2010) 0.92
The PI3K effector Arap3 interacts with the PI(3,4,5)P3 phosphatase SHIP2 in a SAM domain-dependent manner. Cell Signal (2007) 0.92
Novel hydrolysis-resistant analogues of cyclic ADP-ribose: modification of the "northern" ribose and calcium release activity. Biochemistry (2002) 0.91
Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD hydrolase. J Biol Chem (2009) 0.91
Synthesis and biological activity of PTEN-resistant analogues of phosphatidylinositol 3,4,5-trisphosphate. J Am Chem Soc (2006) 0.91
Anti-cancer activities of novel D-ring modified 2-substituted estrogen-3-O-sulfamates. J Steroid Biochem Mol Biol (2005) 0.90
The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol (2003) 0.90
First enzymatic synthesis of an N1-cyclised cADPR (cyclic-ADP ribose) analogue with a hypoxanthine partial structure: discovery of a membrane permeant cADPR agonist. Chem Commun (Camb) (2003) 0.90
A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140. Anticancer Res (2008) 0.90
The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology (2008) 0.89
Inositol trisphosphate 3-kinase B (InsP3KB) as a physiological modulator of myelopoiesis. Proc Natl Acad Sci U S A (2008) 0.89
Understanding inositol pyrophosphate metabolism and function: kinetic characterization of the DIPPs. FEBS Lett (2013) 0.89
Direct evidence for ArO-S bond cleavage upon inactivation of Pseudomonas aeruginosa arylsulfatase by aryl sulfamates. Chembiochem (2008) 0.89
SH2-containing inositol 5-phosphatases 1 and 2 in blood platelets: their interactions and roles in the control of phosphatidylinositol 3,4,5-trisphosphate levels. Biochem J (2003) 0.89
The role of calmodulin for inositol 1,4,5-trisphosphate receptor function. Biochim Biophys Acta (2002) 0.88
Activation of IP(3) receptors by synthetic bisphosphate ligands. Chem Commun (Camb) (2009) 0.88
Cell-permeant small-molecule modulators of NAADP-mediated Ca2+ release. Chem Biol (2006) 0.88
Novel inositol phospholipid headgroup surrogate crystallized in the pleckstrin homology domain of protein kinase Balpha. ACS Chem Biol (2007) 0.87
A diverse family of inositol 5-phosphatases playing a role in growth and development in Dictyostelium discoideum. J Biol Chem (2002) 0.87
Dual aromatase-steroid sulfatase inhibitors. J Med Chem (2007) 0.87
2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents. Bioorg Med Chem Lett (2004) 0.87
Steroidomimetic Tetrahydroisoquinolines for the Design of New Microtubule Disruptors. ACS Med Chem Lett (2011) 0.87
SHIP2 overexpression strongly reduces the proliferation rate of K562 erythroleukemia cell line. Biochem Biophys Res Commun (2002) 0.86
8-Bromo-cyclic inosine diphosphoribose: towards a selective cyclic ADP-ribose agonist. Biochem J (2009) 0.86
Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling and arrhythmias in the heart evoked by β-adrenergic stimulation. J Biol Chem (2013) 0.86
Chemoenzymatic synthesis of 7-deaza cyclic adenosine 5'-diphosphate ribose analogues, membrane-permeant modulators of intracellular calcium release. J Org Chem (2008) 0.86
The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. Ann N Y Acad Sci (2009) 0.86
SHIP2 interaction with the cytoskeletal protein Vinexin. FEBS J (2005) 0.86
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. ChemMedChem (2010) 0.86
A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J Steroid Biochem Mol Biol (2005) 0.86
Steroid sulfatase: a pivotal player in estrogen synthesis and metabolism. Mol Cell Endocrinol (2011) 0.86
Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495). ChemMedChem (2011) 0.86
Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Res Treat (2007) 0.86
2'-deoxy cyclic adenosine 5'-diphosphate ribose derivatives: importance of the 2'-hydroxyl motif for the antagonistic activity of 8-substituted cADPR derivatives. J Med Chem (2008) 0.86